AnaptysBio, Inc.
NASDAQ: ANAB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Faga
- Employees
- 104
- Headquarters
- San Diego, United States
- IPO year
- 2017
- Market cap
- $2.5B
- Website
- https://www.anaptysbio.com
Loading ANAB…
Loading profile data…Frequently asked questions about ANAB
What does AnaptysBio, Inc. (ANAB) do?
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB0...
Where does ANAB trade?
AnaptysBio, Inc. (ANAB) trades on the NASDAQ.
What sector is ANAB in?
AnaptysBio, Inc. (ANAB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AnaptysBio, Inc.?
Daniel Faga is the chief executive officer of AnaptysBio, Inc. (ANAB).
Where is AnaptysBio, Inc. headquartered?
AnaptysBio, Inc. is headquartered in United States.
Does ANAB pay a dividend?
AnaptysBio, Inc. (ANAB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANAB go public?
AnaptysBio, Inc. (ANAB) completed its initial public offering in 2017.